B cells, being a source of characteristic antinuclear autoantibodies, play a crucial role in the pathogenesis of systemic lupus erythematosus (SLE). Evidences indicate that alterations in B-cell regulation are responsible for B-cell hyperactivity as seen in SLE. T cells, soluble factors, and even B cells themselves regulate effector B-cell functions. The latter, so-called regulatory B cells possess regulatory function through production of the cytokine interleukin-10 (IL-10) that can damp down the humoral immune responses. This review will focus on B-cell regulation in the pathogenesis of SLE as a target for intervention. In particular, the regulatory impact of T cells through costimulation, soluble factors such as B lymphocyte stimulator, and the characteristics of IL 10–producing regulatory B cells will be discussed. Therapies targeting B cells as well as B-cell regulation seem promising, but the precise mechanisms involved in these interventions are not completely understood. More insight into B-cell regulation in SLE, and particularly in regulatory B cells, could lead to novel therapeutic strategies.
1 Chan OT Hannum LG Haberman AM Madaio MP Shlomchik MJ . A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med1999; 189: 1639–1648.
2.
2 Matsushita T Yanaba K Bouaziz JD Fujimoto M Tedder TF . Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J Clin Invest2008; 118: 3420–3430.
3.
3 Mauri C Gray D Mushtaq N Londei M . Prevention of arthritis by interleukin 10-producing B cells. J Exp Med2003; 197: 489–501.
4.
4 Lipsky PE . Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol2001; 2: 764–766.
5.
5 Hahn BH . Antibodies to DNA. N Engl J Med1998; 338: 1359–1368.
6.
6 Hochberg MC . Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1997; 40: 1725.
7.
7 Vlahakos D Foster MH Ucci AA Barrett KJ Datta SK Madaio MP . Murine monoclonal anti-DNA antibodies penetrate cells, bind to nuclei, and induce glomerular proliferation and proteinuria in vivo. J Am Soc Nephrol1992; 2: 1345–1354.
8.
8 Jacob L Lety MA Louvard D Bach JF . Binding of a monoclonal anti-DNA autoantibody to identical protein(s) present at the surface of several human cell types involved in lupus pathogenesis. J Clin Invest1985; 75: 315–317.
9.
9 Zhao Z Deocharan B Scherer PE Ozelius LJ Putterman C . Differential binding of cross-reactive anti-DNA antibodies to mesangial cells: the role of alpha-actinin. J Immunol2006; 176: 7704–7714.
10.
10 Faaber P Rijke TP van de Putte LB Capel PJ Berden JH . Cross-reactivity of human and murine anti-DNA antibodies with heparan sulfate. The major glycosaminoglycan in glomerular basement membranes. J Clin Invest1986; 77: 1824–1830.
11.
11 Sun KH Yu CL Tang SJ Sun GH . Monoclonal anti-double-stranded DNA autoantibody stimulates the expression and release of IL-1beta, IL-6, IL-8, IL-10 and TNF-alpha from normal human mononuclear cells involving in the lupus pathogenesis. Immunology2000; 99: 352–360.
12.
12 Chan OT Madaio MP Shlomchik MJ . B cells are required for lupus nephritis in the polygenic, Fas-intact MRL model of systemic autoimmunity. J Immunol1999; 163: 3592–3596.
13.
13 Steinmetz OM Velden J Kneissler U . Analysis and classification of B-cell infiltrates in lupus and ANCA-associated nephritis. Kidney Int2008; 74: 448–457.
14.
14 Fillatreau S Sweenie CH McGeachy MJ Gray D Anderton SM . B cells regulate autoimmunity by provision of IL-10. Nat Immunol2002; 3: 944–950.
15.
15 Mizoguchi A Mizoguchi E Takedatsu H Blumberg RS Bhan AK . Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity2002; 16: 219–230.
16.
16 Singh A Carson WF Secor ER . Regulatory role of B cells in a murine model of allergic airway disease. J Immunol2008; 180: 7318–7326.
17.
17 Duddy ME Alter A Bar-Or A . Distinct profiles of human B cell effector cytokines: a role in immune regulation. J Immunol2004; 172: 3422–3427.
18.
18 Yin Z Bahtiyar G Zhang N . IL-10 regulates murine lupus. J Immunol2002; 169: 2148–2155.
19.
19 Ishida H Muchamuel T Sakaguchi S Andrade S Menon S Howard M . Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J Exp Med1994; 179: 305–310.
20.
20 Llorente L Richaud-Patin Y Garcia-Padilla C . Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum2000; 43: 1790–1800.
21.
21 Looney RJ Anolik JH Campbell D . B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum2004; 50: 2580–2589.
22.
22 Anolik JH Barnard J Cappione A . Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum2004; 50: 3580–3590.
23.
23 Finckh A Ciurea A Brulhart L . ; Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis.B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum2007; 56: 1417–1423.
24.
24 Gunnarsson I Sundelin B Jonsdottir T Jacobson SH Henriksson EW van Vollenhoven RF . Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum2007; 56: 1263–1272.
25.
25 Isenberg D Gordon C Merrill J Urowitz M . New therapies in systemic lupus erythematosus - trials, troubles and tribulations.... working towards a solution. Lupus2008; 17: 967–970.
26.
26 Albert D Dunham J Khan S . Variability in the biological response to anti-CD20 B-cell depletion in SLE. Ann Rheum Dis 2008; 67: 1724–1731.
27.
27 Cambridge G Leandro MJ Teodorescu M . B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum2006; 54: 3612–3622.
28.
28 Sfikakis PP Souliotis VL Fragiadaki KG Moutsopoulos HM Boletis JN Theofilopoulos AN . Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. Clin Immunol2007; 123: 66–73.
29.
29 Vigna-Perez M Hernandez-Castro B Paredes-Saharopulos O . Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther2006; 8: R83.
30.
30 Kinoshita K Tesch G Schwarting A Maron R Sharpe AH Kelley VR . Costimulation by B7-1 and B7-2 is required for autoimmune disease in MRL-Faslpr mice. J Immunol2000; 164: 6046–6056.
31.
31 Liang B Kashgarian MJ Sharpe AH Mamula MJ . Autoantibody responses and pathology regulated by B7-1 and B7-2 costimulation in MRL/lpr lupus. J Immunol2000; 165: 3436–3443.
32.
32 Mihara M Tan I Chuzhin Y . CTLA4Ig inhibits T cell-dependent B-cell maturation in murine systemic lupus erythematosus. J Clin Invest2000; 106: 91–101.
33.
33 Kremer JM Genant HK Moreland LW . Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum2008; 58: 953–963.
34.
34 Bijl M Horst G Limburg PC Kallenberg CG . Expression of costimulatory molecules on peripheral blood lymphocytes of patients with systemic lupus erythematosus. Ann Rheum Dis2001; 60: 523–526.
35.
35 Abe K Takasaki Y Ushiyama C . Expression of CD80 and CD86 on peripheral blood T lymphocytes in patients with systemic lupus erythematosus. J Clin Immunol1999; 19: 58–66.
36.
36 Patschan S Dolff S Kribben A . CD134 expression on CD4+ T cells is associated with nephritis and disease activity in patients with systemic lupus erythematosus. Clin Exp Immunol2006; 145: 235–242.
37.
37 Zhou YB Ye RG Li YJ Xie CM Wu YH . Effect of anti-CD134L mAb and CTLA4Ig on ConA-induced proliferation, Th cytokine secretion, and anti-dsDNA antibody production in spleen cells from lupus-prone BXSB mice. Autoimmunity2008; 41: 395–404.
38.
38 Boumpas DT Furie R Manzi S . BG9588 Lupus Nephritis Trial Group. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum2003; 48: 719–727.
39.
39 Hsu BL Harless SM Lindsley RC Hilbert DM Cancro MP . Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators. J Immunol2002; 168: 5993–5996.
40.
40 Gross JA Johnston J Mudri S . TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature2000; 404: 995–999.
41.
41 Zhang J Roschke V Baker KP . Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol2001; 166: 6–10.
42.
42 Petri M Stohl W Chatham W . Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum2008; 58: 2453–2459.
43.
43 Furie R Stohl W Ginzler EM . ; Belimumab Study Group.Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther2008; 10: R109.
44.
44 Vallerskog T Heimburger M Gunnarsson I . Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther2006; 8: R167.
